0
By clicking the button, I accept the Terms of Use of the service and its Privacy Policy, as well as consent to the processing of personal data.
Don’t have an account? Signup
Supernus Pharmaceuticals announced that the U.S. FDA has yet again declined to approve its drug-device combination therapy for the treatment of mobility symptoms associated with Parkinson’s disease.
Share this article
If you liked this article share it with your friends.they will thank you later